#biopharmaceuticals (1 Posts)
- 
                        
                         Celltrion Launches Affordable Biosimilars in the U.S. Market: A Game Changer for Patients! Celltrion launches denosumab biosimilars Stoboclo and Osenvelt in the US market, tapping into a $6.5 billion opportunity. Celltrion Launches Affordable Biosimilars in the U.S. Market: A Game Changer for Patients! Celltrion launches denosumab biosimilars Stoboclo and Osenvelt in the US market, tapping into a $6.5 billion opportunity.
 
              
Hot Topics